EGCG alleviated nonalcoholic fatty liver disease (NAFLD) in rats by reducing oxidative stress and inflammation by inhibiting PI3K/AKT/FOXO1 and NF-κB pathways [92]. This evidence concerns the gene FOXO1 and metabolic dysfunction-associated steatotic liver disease.